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Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing disease of the skin and the
underlying soft tissue. Fat tissue necrosis accompanied by minimal inflammation is considered the most reliable
histopathologic feature of BU. There may be a constant influx of inflammatory cells to the sites of active
infection but these are thought to be killed by mycolactone, a polyketide toxin produced by M. ulcerans,
through apoptosis and necrosis. Here we describe the spatial correlations between mycobacterial load and the
expression of dendritic cell (DC) surface markers (cluster of differentiation (CD)83, CD11c, and CD123), the Toll-
like receptor (TLR) 9 and pro- and anti-inflammatory cytokines (IL-8, IL-6, tumor necrosis factor-alpha (TNF-a),
IFN-a, IL-12p40, IL-10, and IFN-g) within BU lesions. Although IL-8, IL-6, and TNF-a messenger RNA (mRNA) was
detectable by real-time PCR in all lesions, the expression of the other cytokines was only found as small foci in
some lesions. Correlations of the distribution of mRNA encoding the activation marker CD83 and the DC subset
markers CD123 and CD11c indicate that both activated plasmacytoid and myeloid dendritic cells were present in
the lesions. Results suggest that M. ulcerans specific immune responses may develop once therapeutic
interventions have limited the production of mycolactone.
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INTRODUCTION
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a
chronic necrotizing disease of skin and soft tissue. Generally
it manifests initially as firm, non-tender, subcutaneous
nodules, probably at the sites of penetrating skin trauma
(pre-ulcerative stage). Subsequently, these areas become
fluctuant, followed by the formation of an ulceration with
undermined edges (ulcerative stage). Ulcers can be extensive,
involving more than 10% of the patient’s skin surface
(Johnson et al., 2005). Subcutaneous fat is particularly
affected, but underlying bone may also become involved in
advanced cases. In BU lesions clumps of extracellular acid-
fast bacilli surrounded by areas of necrosis are found. Fat
tissue necrosis accompanied by minimal inflammation is
considered the most reliable histopathologic feature of BU
(Hayman and McQueen, 1985; Hayman, 1993; Guarner
et al., 2003). In late stages of the disease, intralesional influx
of leukocytes and granulomatous responses in the dermis and
panniculus has been described. If left untreated, spontaneous
healing of BU lesions can occur after extended periods of
progressive ulceration (Asiedu et al., 2000). Traditionally, BU
is treated by wide surgical excision, drug therapy has been
considered ineffective, but recent data suggest that combina-
tions of anti-mycobacterial antibiotics can support or replace
surgical treatment (Etuaful et al., 2005). Provisional World
Health Organization (WHO) guidelines now recommend
the use of rifampicin and streptomycin for the treatment
of BU (http://www.who.int/buruli/information/antibiotics/en/
index1.html).
M. ulcerans is unique among mycobacterial pathogens
in that it is mainly extracellular and produces a plasmid-
encoded toxin with a polyketide-derived macrolide
structure, named mycolactone (Stinear et al., 2004). Myco-
lactone is believed to play a central role in determining
the extracellular localization of the bacteria and modulation
of immunological responses to M. ulcerans (Adusumilli
et al., 2005). Observations in rodents experimentally infected
with mycolactone producing and mycolactone-negative
M. ulcerans strains suggested that inflammatory cells are
rapidly killed by necrosis when encountering high toxin
concentrations. Inflammatory cells more distant from the
necrotic center are thought to be killed via apoptosis resulting
in extracellular bacteria surrounded by an area of coagulation
necrosis. In contrast, granulomatous lesions with strong
self-healing tendencies were observed with mycolactone-
negative mutants (Oliveira et al., 2005).
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Intrigued by the described lack of inflammatory responses
in BU lesions, we have analyzed the impact of M. ulcerans
infection on the activation of the skin innate immune system,
including dendritic cells (DC). Here we describe the spatial
correlations between bacterial load and the expression of
DC-surface markers (cluster of differentiation (CD)83,
CD11c, and CD123), the intracellular receptor Toll-like
receptor (TLR)9 and pro- and anti-inflammatory cytokines
(IL-8, IL-6, tumor necrosis factor-alpha (TNF-a), IFN-a,
IL-12p40, IL-10, and IFN-g) within BU lesions.
RESULTS
Quantitative real-time PCR was used to determine the
spatial distribution of messenger RNA (mRNA) encoding
cytokines and cell-surface markers of the innate immune
system within surgically excised early ulcerative BU lesions
of three selected patients. Histopathological changes and
M. ulcerans DNA levels in the same tissue samples have
been described previously (Rondini et al., 2006). A summary
of these data is provided in Figures 1 and 2 for direct
comparison with the distribution of cytokine and DC marker
mRNA.
Distribution of DC marker mRNA
Figure 1 shows the spatial pattern of mRNA encoding the
cell-surface marker CD83, CD11c, CD123, and the intra-
cellular receptor TLR9. Percent values normalized to b-actin
mRNA are provided. In all three patients CD83 (Figure 1d–f)
and CD123 mRNA (Figure 1j–l) was detectable along the
entire lesions. Relative levels ranged from 0 to 4.2% (as
compared to 0.270.1% in normal skin) and from 0 to 7.4%
(0.270.2% in normal skin), respectively. CD11c (Figure 1g–i)
and TLR9 mRNA (Figure 1m–o) showed a more focal
distribution with relative levels ranging from 0 to 92%
(0.470.2% in normal skin) and 0–1.2% (o0.01% in normal
skin), respectively. For all four markers peak values were thus
much higher than in normal skin. In many cases peaks were
located close to foci of M. ulcerans DNA (sample G in patient
A, samples D and F in patient B, and samples D and E in
patient C).
Distribution of cytokine mRNA
Expression of cytokines with pro-inflammatory or anti-
inflammatory activity was analyzed (Figure 2). IL-8, IL-6,
and TNF-a mRNA was detectable in all three BU lesions,
albeit in different amounts and in markedly different spatial
patterns. Peaks of the relative levels of IL-8 mRNA were
associated with the ulcerations and the histological detection
of neutrophils (Figure 2a–c). In contrast, location of the
relative peaks of IL-6 mRNA with respect to the location of
ulcerations and peaks of M. ulcerans DNA varied markedly
between lesions. In patient A, the relative IL-6 mRNA levels
were highest at the less affected borders of the excised tissue,
in patient B it was peaking at the nodular pre-ulcerative
lesion and in patient C at and around the ulceration (Figure
2d–f). TNF-a mRNA was broadly distributed over the lesion.
Relative peak levels of IL-8, IL-6, and TNF-a mRNA (130.395,
10, and 2.3%, respectively) were dramatically higher than the
levels found in normal skin (4.775.1, 0.170.1, and 0.17
0.1%, respectively).
Like in normal skin, IL-12p40 mRNA levels were below
the detection limit in all three BU lesions analzsed (o0.03%)
(data not shown). In contrast, IFN-a, IFN-g, and IL-10 mRNA,
also undetectable in normal skin, was found at least in one of
the three analyzed lesions in spatially highly restricted foci.
IL-10 and IFN-g mRNA was detected only in patient B (Figure
2n). Although a peak of IL-10 mRNA was associated with the
secondary non-ulcerated nodule (peak value 1.2%), IFN-g
mRNA was found in one sample close to the small ulceration
and the associated granulomas (peak value 0.2%) (Figure 2n).
Significant levels of IFN-a mRNA were primarily found in
patient C (Figure 2j–l), peaking towards the right margin of the
excised tissue (Figure 2l, peak value in sample I, 246%).
Correlations of the spatial distribution of mRNA species
The spatial mRNA distributions of the two DC subset markers
CD11c and CD123 were positively correlated with that of the
cellular maturation marker CD83 (CD83 vs CD123: r¼0.63,
Po0.0001; CD83 vs CD11c: r¼ 0.54, P¼0.001; Figure 3a
and b). Also strong positive correlations of the distribution of
CD83 with IL-6 and TNF-a were observed (r¼0.67,
Po0.0001, and r¼ 0.80, Po0.0001, respectively; Figure 3c
and d). Correlation of IL-6 expression with CD123 was tighter
(r¼0.66, Po0.001; Figure 3e) compared with CD11c
(r¼0.41, P¼ 0.02; Figure 3f). The correlation of both DC
subset markers with TNF-a expression was moderate (CD11c
vs TNF-a: r¼ 0.50, P¼ 0.002; CD123 vs TNF-a: r¼0.48,
P¼0.004; data not shown). There was no indication of a
correlation between IFN-a and CD123, CD83, or CD11c
(data not shown).
Immunohistochemical detection of CD123 and TLR9-positive
cells
Results of quantitative real-time PCR and immunohistochem-
istry were highly associated, that is the relative numbers of
CD123 and TLR9-positive cells were consistent with the
mRNA levels detected by real-time PCR (Figure 4). In the thin
sections of lesions positive for CD123 and TLR9 mRNA,
CD123, and TLR9 antibodies stained cells with plasmacytoid
features (inset Figure 4b and d).
DISCUSSION
Under homeostatic conditions, cutaneous DCs include
epidermal Langerhans cells and interstitial/dermal DCs that
are of myeloid origin (Kupper and Fuhlbrigge, 2004). Our
real-time PCR and immunostaining data indicate that in
addition to the CD11c-positive CD123-negative myeloid DCs
(Colonna et al., 2004), CD123-positive plasmacytoid DCs
(P-DC), are present in early ulcerative lesions. P-DC are of
lymphoid origin (Colonna et al., 2004), CD11c-negative and
known to be recruited to diseased skin in conditions such as
systemic lupus erythematosus, atopic dermatitis, psoriasis
vulgaris, and contact dermatitis (Wollenberg et al., 2002;
Bangert et al., 2003; Nestle et al., 2005).
One of the surface molecules upregulated upon DC
activation and maturation is CD83 (Lechmann et al., 2002).
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Although CD83 is also expressed on activated human B and T
cells and a subpopulation of activated monocytes (Lechmann
et al., 2002), the observed correlations of mRNA expression
between CD83 and CD123, or CD11c indicated, that both
P-DC and myeloid DC were activated in the BU lesions. The
distribution of mRNA encoding the highly expressed pro-
inflammatory cytokines IL-6 and TNF-a was also strongly
correlated with the activation marker CD83. Expression of
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Figure 1. Spatial localization of bacterial load and DC markers in BU lesions. Patients A, B, and C excisions with tissue samples: A–N, A–K, A–I; respectively.
Relative quantity of mRNA for the surface markers (d–f) CD83, (g–i) CD11c, (j–l) CD123, and (m–o) intracellular receptor TLR9 expressed in percent relative
to b-actin gene expression. (a–c) M. ulcerans DNA load and histopathological changes of the excisions (Rondini et al., 2006).
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IL-6 was additionally strongly correlated with that of CD123,
indicating that activated P-DC may represent the major
source of IL-6 expression in the BU lesions. In contrast to
myeloid DC, P-DC express TLR7 and TLR9 but lack TLR2,
TLR3, TLR4, and TLR5. In the majority of patient samples
analyzed, expression of TLR9 and CD123 mRNA was
consistent, supporting the presence of P-DC in BU lesions
(Figure 1). Signalling through TLR7 and TLR9 results in P-DC
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Figure 2. Distribution of bacterial load and cytokine mRNA in BU excisions. Patient A, B, and C excisions with tissue samples: A–N, A–K, A–I; respectively.
Relative quantity of mRNA for the cytokines (a–c) IL-8, (d–f) IL-6, (g–i) TNF-a, (j–l) IFN-a, (m–o) IL-10 and IFN-g expressed in percent relative to b-actin
gene expression. (a–c) M. ulcerans DNA load and histopathological changes of the excisions (Rondini et al., 2006).
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activation to secrete large amounts of type I IFN and
moderate amounts of TNF-a and IL-6 (Colonna et al.,
2004). In contrast to IL-6, no correlation between CD123
and IFN-a mRNA was observed. IFN-a expression by P-DC
seems to be variable; whereas P-DC activation by TLR9 in
response to viruses results in secretion of large amounts of
IFN-a (Colonna et al., 2004), during the development of
psoriatic phenotype IFN-a expression by P-DC seems to be
only an early and transient event (Nestle et al., 2005).
Consistent with published data (Prevot et al., 2004; Kiszewski
et al., 2006; Phillips et al., 2006), TNF-a and IL-8 mRNA
levels were, like those of IL-6 and IFN-a mRNA, much higher
in the BU lesions than in normal skin. As moderate
correlation between DC markers and TNF-a mRNA was
observed, TNF-a mRNA expression may be in part associated
with other cell types, like monocytes, activated T cells, or
natural killer cells.
The mechanism of immune protection in M. ulcerans
remains unclear. Evidence from genetic defects in the IFN-g
signalling pathway supports the role of IFN-g in protection
against a range of non-tuberculous mycobacterial disease,
including M. ulcerans (Ottenhoff et al., 2005). Peripheral
blood mononuclear cells from BU patients with active
disease showed significantly reduced lympho-proliferation
and IFN-g production in response to stimulation with live or
dead M. bovis Bacillus Calmette-Gue´rin, M. ulcerans,
purified protein derivative of M. tuberculosis, isopentenyl
pyrophosphate, and non-mycobacterial antigens like recon-
stituted influenza virosomes (Gooding et al., 2001, 2002,
2003; Prevot et al., 2004; Yeboah-Manu et al., 2006). Prevot
et al. (2004) showed with semiquantitative PCR analyses that
the systemic Th1 downmodulation was mirrored by local,
intralesional cytokine profiles. High IFN-g with low IL-10
mRNA levels were present in early, nodular lesions, and low
IFN-g mRNA levels were detected in late ulcerative lesions
(Prevot et al., 2004). Hence, in active M. ulcerans disease, the
Th1 response seemed to be downregulated both locally and
systemically. The presence of IL-6 during T-cell priming may
promote Th2 differentiation and simultaneously inhibit Th1
polarization (Diehl and Rincon, 2002). Therefore the close
association of CD123 (P-DC) with IL-6 in conjunction with
the lack of IFN-a production may favor Th2 development and
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Figure 3. Correlations of DC markers and cytokine expression. Patient A (K), B (~), and C (þ ). Spearman’s correlations of the mRNA spatial distribution
in the excisions are given. (a) CD123 versus CD83; (b) CD11c versus CD83; (c) IL-6 versus CD83; (d) TNF-a versus CD83; (e) IL-6 versus CD123; (f) IL-6 versus
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result in the observed Th1 downmodulation in BU. IL-6 is a
pleiotropic cytokine involved in the growth and differentia-
tion of numerous cell types, including those of dermal and
epidermal origin (Paquet and Pierard, 1996). In the skin, it is
induced in a broad range of dermatotoxic reactions and may
be involved in wound healing (Hernandez-Quintero et al.,
2006). The presence of high numbers of P-DC in the lesions
in the absence of IFN-a gene expression raises also the issue
of a tolerogenic role of these cells, as suggested in primary
cutaneous melanomas (Vermi et al., 2003).
IL-10 and IFN-g mRNA was detected in one of the three
analyzed BU lesions, where it was present only in highly
focal areas. Phillips et al. (2006) showed wide variations in
IL-10 and IFN-g mRNA expression among individual skin
punch biopsies. Generally, our results demonstrate that
expression of cytokines and cell-surface markers can vary
considerably within a BU lesion. Therefore, results obtained
with biopsies of BU lesions do not necessarily reflect the
overall profile of a lesion. Our comparison of the spatial
relationship between bacterial load, DC marker, and pro-
inflammatory cytokine mRNA suggests that the presence of
clusters of M. ulcerans does not exclude innate immune
system recruitment to the site of infection. This conclusion is
consistent with the hypothesis of Oliveira et al. (2005)
suggesting a constant influx of neutrophils, monocytes/
macrophages, and lymphocytes to active M. ulcerans lesions.
Potentially, M. ulcerans specific immune responses may
therefore develop, once a therapeutic intervention, such as a
successful antibiotic treatment, is limiting the production of
mycolactone.
MATERIALS AND METHODS
Clinical specimens
Three BU patients with ulcerative lesions, who received standard
treatment at the Amasaman Health Centre in the Ga district in
Ghana, were enrolled in this study. The standard treatment
comprised wide surgical excision including margins of macroscopi-
cally healthy tissue followed by skin grafting. BU clinical diagnosis
was reconfirmed by IS2404 PCR, microscopic detection of acid-fast
bacilli, and observation of characteristic histopathological changes.
The distribution of M. ulcerans DNA and histopathological
examination within the excised tissue samples analyzed here, have
been described elsewhere (Rondini et al., 2006). Patient A presented
with an ulcerated plaque (ulcer size 4 5 cm) on the dorsal aspect of
the left upper arm. The central necrotic slough was associated with
typical inflammatory cells whereas no granulomas were seen in any
zone of the excision. The highest mycobacterial DNA burden was
present at the base of the ulcer and decreased towards the margins of
the excision (Figure 1a). Patient B presented with a small-ulcerated
lesion (+ 1 cm) and a larger non-ulcerated nodule located about
3 cm apart on the dorsal aspect of the right elbow. The M. ulcerans
DNA was present with high load within the non-ulcerated nodule
and, with lower load, in the ulcerated region. Between these two
lesions no bacterial DNA was detected. Granulomas were present
across the tissue from nodule to ulcer till the right margin of the
excision (Figure 1b). Patient C presented with a small ulcer 5 cm
away from a larger ulcer, which was surrounded by scar tissue and
showed evidence of previous treatment. M. ulcerans DNA was only
present at the base of the small ulcer and no granulomas were
detected in the whole excision (Figure 1c). Ethical approval for
analyzing patient specimens was obtained from the local ethical
review board of the Noguchi Memorial Institute for Medical
Research and participants gave their written informed consent. The
study was conducted according to the Declaration of Helsinki
Principles.
RNA extraction, removal of genomic DNA, and reverse
transcription
RNA was extracted from several samples of equal size, each
comprising skin and fat tissue, which were obtained from BU
patients’ excised lesions: patient A, 14 samples (A–N); patient B, 11
samples (A–K); patient C, nine samples (A–I). Samples were disrupted
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Figure 4. Immunohistochemical analysis of P-DC recruitment to BU excisions. Immunohistochemical stainings in thin sections of tissues samples B and F
of patient B. (a, b) CD123 staining (original magnification  100, inset original magnification  400) and (c, d) TLR9 staining (original magnification  200,
inset original magnification  1,000), bars¼40 mm.
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by sonication for 2 minutes (Sonifers Branson 250, Branson
Ultrasonics Corporation, Danbury, CT) and centrifuged for 3 minutes
at 10,000 g. RNA was extracted from the tissue lysate using the
RNeasy Mini Kit (Qiagen AG, Basel, CH) and treated with DNase I
(Invitrogen, Paisley, UK) to remove genomic DNA.
To synthesize complementary DNA, total RNA was incubated
with oligo d(T) for 10 minutes at 651C, and put on ice. A reaction
mixture containing dNTP mix (125 nM), dithiothreitol (10 mM) and
reverse transcriptase Moloney murine leukemia virus (200 U) with
corresponding first strand buffer was added (Invitrogen, Paisley, UK).
The reaction mix was incubated for 60 minutes at 371C before
enzyme inactivation for 5 minutes at 941C.
Quantitative real-time polymerase chain reaction
Gene transcription was evaluated using the ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster City, CA).
Primers and probes for six human cytokines (IL-6, IL-8, IL-10,
IL-12p40, TNF-a, IFN-a, and IFN-g), cell-surface proteins (CD11c,
CD83, CD123, and TLR9) were used to amplify specific comple-
mentary DNA in duplicate, according to the manufacturers
instructions (Applied Biosystems, Foster City, CA). The b-actin gene
was used as an internal house keeping gene reference. Primers and
probes for b-actin, IL-8, IL-12p40, IFN-a, CD11c, CD83, CD123,
and TLR9 were obtained from Applied Biosystems. Primer and
probes for IL-6 (Hartwig et al., 2002), IL-10 (Giulietti et al., 2001),
TNF-a (Razeghi et al., 2001), and IFN-g (Kammula et al., 1999) were
synthesized by Mycrosynth (Balgach, CH). Having verified that the
amplification dynamic remains proportional at all tested dilutions,
RNA expression of each surface marker and cytokine was presented
as percentage relative to b-actin gene expression. The assays were
run in duplicates and the results with a standard deviation 42%
were excluded. Correlation analyses were performed in Prism using
the Spearman rank correlation coefficient. Mean values of surface
markers and regulatory cytokines in six samples of healthy skin tissue
are as follow: CD11c (0.470.2%), CD123 (0.270.2%), CD83
(0.270.1%), TLR9 (o0.01%), TNF-a (0.170.1%), IL-6 (0.170.1%),
and IL-8 (4.775.1%). IFN-a, IFN-g, IL-10, and IL-12p40 mRNA were
undetectable.
Immunohistochemistry
Tissue samples were fixed overnight in neutral buffered 4%
paraformaldehyde, embedded in paraffin according to standard
protocol and cut into 5mm sections using a microtome. After de-
paraffinization, sections were re-hydrated through graded alcohols
and washed in distilled water. Antigen retrieval was performed by
microwave unmasking technique in 10 mM EDTA pH 8.0. Subse-
quently, endogenous peroxidase was blocked with 0.3% H2O2 for
30 minutes and unspecific binding prevented by incubating with
blocking serum for 20 minutes at room temperature. CD123 (clone
6H6) and TLR9 (clone eB72-1665) antibodies (eBiosciences, San
Diego, CA) were diluted 1:100 and 1:1,000, respectively, in
phosphate-buffered saline plus 0.1% Tween-20 and slides incubated
in a humid chamber for 1 hour at room temperature. Sections were
incubated for 30 minutes at room temperature with the secondary
antibody biotin labelled (Vector Laboratories; 1:200 in phosphate-
buffered saline). Slides were then labelled with streptavidin horse-
radish peroxidase conjugate (Vector Laboratories, Vectastain Elite
ABC kit) for 30 minutes at room temperature and staining was
performed by using Vector NovaRed and hematoxylin (counter
stain).
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